about
Prevalence and correlates of hepatitis C virus infection among inmates entering the California correctional system.Chronic viral hepatitis C: management updateA Substituted Tetrahydro-Tetrazolo-Pyrimidine Is a Specific and Novel Inhibitor of Hepatitis B Virus Surface Antigen SecretionGeneral Epidemiological Parameters of Viral Hepatitis A, B, C, and E in Six Regions of China: A Cross-Sectional Study in 2007Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell cultureRole of lamivudine in the treatment of chronic hepatitis B virus infectionIntroduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data.A peptide mimetic of human interferon (IFN)-beta.Elimination of duck hepatitis B virus RNA-containing capsids in duck interferon-alpha-treated hepatocytes.Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).Duck hepatitis B virus replication in primary bile duct epithelial cells.In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovirCharacterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucksTreatment of hepatitis C with interferon and ribavirin.Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection.Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion.Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients.Chronic hepatitis B infection in Canada.Targeted ribonuclease can inhibit replication of hepatitis B virus.Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial.Short-term intravenous interferon therapy for chronic hepatitis B.A new era in the treatment of chronic hepatitis C infection.Phylogenetic characterization of genotype 4 hepatitis C virus isolates from Argentina.Hepatitis C and substance use in a sample of homeless people in New York City.Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus.Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.In vitro evaluation of 9-(2-phosphonylmethoxyethyl)adenine ester analogues, a series of anti-HBV structures with improved plasma stability and liver release.The tandem-repeat polymorphism of the DC-SIGNR gene in HCV infection.Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA.Quality of life in HCV-infection: lack of association with ALT levels.Expression of interferon alfa signaling components in human alcoholic liver disease.Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases.Inhibition of hepatitis B virus replication in 2.2.15 cells by expressed shRNA.Significant interference with hepatitis B virus replication by a core-nuclease fusion protein.
P2860
Q24538613-955A4628-3CB1-4727-B6A4-5EDE8AA7D64AQ27471844-16734552-4537-4099-AB46-69F4EECD79F0Q27484471-91DB9102-45D6-4952-901E-47DDA018B7CDQ27490512-A36FB5D1-E5D4-4794-A179-9413FF304932Q28373274-5647804E-64C0-4AE4-BA4B-577BB2D9A94DQ28375031-C24BBBEB-FF21-4247-9D46-8E66B326E8BEQ30689186-1F1716D2-C075-4A70-81A6-F1EA2C288D4EQ30882993-643FC9CA-717A-48EF-9B6C-60CACF158F56Q33815092-C33B61AE-C5A0-42AB-883C-8EB966A43630Q33840970-260416DF-FE6D-4995-8371-EC9304E6DE42Q33852986-575F2B08-DDA3-4DEB-A8A5-2CE017318C87Q33978910-C16F6659-6805-417E-8F7A-5929399E30D5Q33981009-424C120F-7B26-451B-9D9D-9962A1603B9BQ33983079-847988E7-C5BC-4E5A-8543-2CEA1E16A729Q33988146-E5B721B2-7E4A-48C8-ADA9-0AC48C2B7E00Q34365631-19560D2E-73D6-4EBB-976F-729E87BBBD92Q35171063-E9D52188-BD15-4B76-B351-1D4F8386BCF4Q36151267-92EFAB4E-4E47-48AE-BD3E-FD544C7EC1EAQ36170444-884B45D6-8773-4E60-B9ED-E68944DBED79Q36178340-F2582798-4828-4939-9533-A7728CDF98A2Q36190663-9374E2C1-B616-4958-990E-1F03D95CDEA3Q37265596-A6E6E67C-E2A1-491A-97A2-F1AB00F1F779Q38051248-E93A5768-5792-488B-BAAB-1B02996E6113Q39464752-93F17979-080D-4875-B300-736AE361ED73Q39588691-18AD5652-41DB-4E2E-BD56-45869E73D10DQ39652022-93E08C7C-4150-441B-BE91-A344CAC1B5D3Q40887887-34E23C6B-0B36-4959-B2EB-09B33295AD87Q42249059-981A0691-A107-4839-BBD8-723CA44FBF20Q42997232-3BC5BBD0-8E50-4684-8D7F-A40B690030A4Q43036076-39CBCD60-6618-47AA-9CBC-10CEF0C99B2DQ43724091-9EA3482C-6BCD-4462-82DA-631A169E3C43Q43875858-8DC12519-61DA-4527-BD9A-02FE13525F51Q43982840-016F85A0-7686-4210-850A-37A01F5D238CQ45474715-A5059D8D-34F4-4BDF-B184-59A069ABE45AQ45739285-06AE3B4B-9EBB-4203-BCD6-98844AAB592F
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Therapy of viral hepatitis.
@en
type
label
Therapy of viral hepatitis.
@en
prefLabel
Therapy of viral hepatitis.
@en
P356
P1433
P1476
Therapy of viral hepatitis.
@en
P2093
Hoofnagle JH
P304
P356
10.1159/000007532
P577
1998-08-01T00:00:00Z